Recombinant, chimaeric live, attenuated vaccine (ChimeriVax(TM))) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates

Vaccine

Volumn 17, Issue 15-16, 1999, Pages 1869-1882

  Monath, T P ^a   Soike, K ^b   Levenbook, I ^c   Zhang, Z X ^a   Arroyo, J ^a   Delagrave, S ^a   Myers, G ^a   Barrett, A D T ^d   Shope, R E ^d   Ratterree, M ^b   Chambers, T J ^e   Guirakhoo, F ^a  

^a Acambis   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c 3228 Prestwick Lane ^*  (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIVAX; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; YELLOW FEVER VACCINE;

ANIMAL MODEL; ANTIBODY TITER; ARTICLE; EPIDEMIC ENCEPHALITIS; IMMUNOGENICITY; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VACCINATION; VIRUS CAPSID; VIRUS ENCEPHALITIS; VIRUS ENVELOPE; YELLOW FEVER;

ANIMALS; CAPSID; CELL LINE; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; MACACA MULATTA; NEUTRALIZATION TESTS; SEQUENCE ANALYSIS, DNA; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS; VIRAL VACCINES; VIREMIA; YELLOW FEVER VIRUS;

EID: 0033538089     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00487-3     Document Type: Article

References (44)

1. Theiler M., Smith H.H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65:1937;787-800.
2. Poland J.D., Calisher C.H., Monath T.P., Downs W.G., Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. WHO. 59:1981;895-900.
3. Monath TP. Yellow fever. In: Plotkin S, Orenstein W, editors. Vaccines. Philadelphia, PA: W.B. Saunders and Company, 1999. In press.
4. Rice C.M., Lenches E.M., Eddy S.R., Shin S.J., Sheets R.L., Strauss J.H. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science. 229:1985;726-733.
5. Post P.R., Santos C.N.D., Carvalho R., Cruz A.C.R., Rice C.M., Galler R. Heterogeneity in envelope protein sequence and N-linked glycosylation among yellow fever virus vaccine strains. Virology. 188:1992;160-167.
6. Duarte dos Santos C.N., Post P.R., Carvalho R., Ferreira I.I., Rice C.M., Galler R. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res. 95:1995;35-41.
7. World Health Organization. WHO Expert Committee on Biological Standardization, 46th Report. WHO Tech. Rep. Ser. No. 872. Geneva: World Health Organization, 1998. p. 30-68.
8. Tsai TF, Yu YX. Japanese encephalitis vaccines. 2nd ed. In Plotkin S, Mortimer E, editors. Vaccines. Philadelphia, PA: WB Saunders and Company, 1995. p. 671-713.
9. Chambers T.J., Tsai T.F., Pervikov Y., Monath T.P. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine. 15:1997;1494-1502.
10. Chambers TJ, Nestorowicz A, Mason PW, Eckels KH, Rice CM. Yellow fever/Japanese encephalitis chimaeric viruses: construction and biological properties. J Virol 1999, in press.
11. Yu Y.X., Wu P., Ao J., Liu L.H., Li H.M. Selection of a better immunogenic and highly attenuated live vaccine virus strain of JE. I. Some biological characteristics of SA14-14-2 mutant. Chin. J. Microbiol. Immunol. 1:1981;77-84.
12. Rice C.M., Grakoui A., Galler R, Chambers T.J. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. N. Biol. 1:1989;285-296.
13. Sumiyoshi H., Tignor G.H., Shope R.E. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J. Infect. Dis. 171:1995;1144-1151.
14. Ni H., Burns N.J., Chang G.-J.J., Zhang M.-J., Wills M.R., Trent D.W., Sanders P.G., Barrett A.D.T. Comparison of nucleotide and deduced amino acid sequence of the 5′ non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J. Gen. Virol. 75:1994;1505-1510.
15. Nitayaphan S., Grant J.G., Chang G.J., Trent D.W. Nucleotide sequence of virulent SA14 strain of Japanese encephalitis and its attenuated derivative. Virology. 177:1990;541-552.
16. Aihara S., Rao C.M., Yu Y.X. Identification of mutations that occurred on the genome of Japanese encephalitis virus during the attenuation process. Virus Genes. 5:1991;95-109.
17. Barrett A.D.T. Yellow fever vaccine. Biologicals. 25:1997;17-26.
18. Clarke D.H., Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am. J. Trop. Med. Hyg. 7:1958;561-573.
19. Levenbook I.S., Pelleu L.J., Elisberg B.L. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and historical examination. J. Biol. Stand. 15:1987;305-313.
20. Nathanson N., Davis M., Thind I.S., Price W.H. Histological studies of the monkey neurovirulence of group B arboviruses. II. Selection of indicator centers. Am. J. Epidemiol. 84:1966;524-540.
21. Theiler M. The virus. In: Strode GK, editor. Yellow fever. New York: McGraw Hill, 1951. p. 46-136.
22. Liu Z.-L., Hennessy S., Strom B.L., Tsai T.F., Wan C.-M., Tang S.-C., Xiang C.-F., Bilker W.B., Pan X.-P., Yao Y.-J., Xu Z.-W., Halstead S.B. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J. Infect. Dis. 176:1997;1366-1369.
23. Hennessy S., Liu Z., Tsai T.F., Strom B.L., Wan C.-M., Liu H.-L., Wu T.-X., Yu H.-J., Liu Q.-M., Karabatsos N., Bilker W.B., Halstead S.B. Effectiveness of live-attenuated hamster kidney cell-derived Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet. 347:1996;1583-1586.
24. Ni H., Chang G.-J.J., Xie H., Trent D.W., Barrett A.D.T. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J. Gen. Virol. 76:1995;409-413.
25. Schlesinger J.J., Chapman S., Nestorowicz A., Rice C.M., Ginocchio T.E., Chambers T.J. Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and nonneuroadapted virus and partial sequence analysis of the neuroadapted strain. J. Gen. Virol. 77:1996;1277-1285.
26. McMinn P.C., Marshall I.D., Dalgarno L. Neurovirulence and neuroinvasiveness of Murray Valley encephalitis virus mutants selected by passage in a monkey kidney cell line. J. Gen. Virol. 76:1995;865-872.
27. Fox J.P., Penna H.A. Behavior of 17D yellow fever virus in rhesus monkeys. Relation to substrain, dose and neural or extraneural inoculation. Am. J. Hyg. 38:1943;152-172.
28. Monath TP. Pathobiology of the Flaviviruses. In: Schlesinger S, Schlesinger MJ, editors. The Togaviridae and Flaviviridae. New York: Plenum Press, 1986. p. 375-440.
29. Tiggert W.D., Berge T.O., Gochenour W.S., Gleiser C.A., Eveland W.C., Bruegge C.V., Smetana H.F. Experimental yellow fever. Trans. N. Y. Acad. Sci. 22:1960;323-333.
30. Nasidi A., Monath T.P., Vandenberg J., Tomori O., Calisher C.H., Hurtgen X., Munube G.R.R., Sorungbe A.O.O., Okafor G.C., Wali S. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans. R. Soc. Trop. Med. Hyg. 87:1993;337-339.
31. Camenga D.L., Nathanson N., Cole G.A. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J. Infect. Dis. 130:1974;634-641.
32. Lubiniecki A.S., Cypess R.H., Hammon W.McD. Passive immunity for arbovirus infection. Am. J. Trop. Med. Hyg. 22:1973;535-542.
33. Zhang M., Wang M., Jiang S., Ma W. Passive protection of mice, goats, and monkeys against Japanese encephalitis with monoclonal antibodies. J. Med. Virol. 29:1989;133-138.
34. + cytoxic T lymphocytes of dengue virus nonstructional proteins NS3 and NS1.2a. J. Clin. Invest. 98:1996;1684-1691.
35. + T-cell clones: flavivirus cross-reactivity, protein recognition, and cytotoxic activity. J. Virol. 72:1998;8032-8036.
36. Konishi E., Yamaoka M., Khin-Sane-Win, Kurane I., Mason P.W. Induction of protective immunity against Japanese encephalitis with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J. Virol. 72:1998;4925-4930.
37. Kreil T.R., Maier E., Fraiss S., Eibl M.M. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J. Virol. 72:1998;3076-3081.
38. Lee H.W., Scherer W.F. The anamnestic antibody response to Japanese encephalitis virus in monkeys and its implications concerning naturally acquired immunity in man. J. Immunol. 86:1960;151-164.
39. Tsai T.F., Yong-Xin Y., Li J.L., Putvatana R., Ran Z., Shougui W., Halstead S.B. Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine-A comparison of 1- and 3-month immunization schedules. J. Infect. Dis. 177:1998;221-223.
40. Harrington D.G., Hilmas D.E., Elwell M.R., Whitmire R.E., Stephen E.L. Intranasal infection of monkeys with Japanese encephalitis virus: clinical response and treatment with a nuclease-resistant derivative of poly(I)-poly(C). Am. J. Trop. Med. Hyg. 26:1977;1191-1198.
41. Nathanson N. Pathogenesis. In: Monath TP, editor. St. Louis Encephalitis. Washington DC: American Public Health Association, 1980. p. 201-36.
42. Johnson R.T., Burke D.S., Elwell M., Leake C.J., Nisalak A., Hoke C.H., Lorsomrudee W. Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann. Neurol. 18:1977;567-576.
43. Schlesinger J.J., Brandriss M.W., Cropp C.B., Monath T.P. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 60:1986;1153-1155.
44. Monath T.P., Craven R.B., Muth D.J., Trautt C.J., Calisher C.H., Fitzgerald S.A. Limitations of the complement-fixation test for distinguishing naturally-acquired from vaccine-induced yellow fever infection in flavivirus hyperendemic areas. Am. J. Trop. Med. Hyg. 29:1980;624-634.